Introduction
Since the first described clinical attempt of slaughtered sheep pancreas transplant in a 13-year-old boy dying of diabetic ketoacidosis in 1894 [1] , other islet transplantation approaches have been attempted over the years. These include the following: islet autografts in patients following near-total or total pancreatectomy, islet allografts in patients following total pancreatectomy, fetal islet allografts or xenografts in patients with type 1 diabetes, islet allografts in patients with type 2 diabetes, and islet allografts in patients with type 1 diabetes. The aim of this review paper is to expose the readers to the radiologic aspects of the procedures and techniques involved in islet cell allograft transplantation for the treatment of type 1 diabetes.
Islet Allografts for Type 1 Diabetes
Recent advances have led to post islet cell transplantation insulin independence rates of up to 80% at 1 year [2] . Multiple centers worldwide are now offering islet cell transplantation as an experimental treatment for select patients with uncontrolled, symptomatic type 1 diabetes. Since the year 2000, an estimated 500 patients Six female patients with type 1 diabetes mellitus for at least 5 years and with undetectable arginine-stimulated C-peptide underwent islet cell transplantation in our institution. The main inclusion criterion was severe recurrent hypoglycemia. Pancreases were received at the NIH from regional organ procurement organizations and the United Network for Organ Sharing. The islet isolation process has been previously described [5] . Only islets with a maximal packed tissue volume of 10 mL or less and with islet purity of at least 30%, gram-stain negative and endotoxin negative were used for transplantation. The isolated islets were suspended in special medium 199 that also contained 50 U of heparin per kilogram of the recipient weight (in order to limit further thrombosis risk of the portal vein during infusion) for the first two patients and one third that dose for the subsequent four patients. The remaining two thirds of the heparin dose (total remained 50 U/kg of the recipient body weight) was injected as a bolus into the portal vein just prior to islet infusion.
Validated techniques for culturing the islets following cell processing were not available at the time of the study, so all transplants were performed immediately, as soon as cell processing was complete. This required the teams to be on call, 24 hours per day. The interventional radiology teams were given notice that a pancreas was being evaluated and processed, and patients were brought in to the hospital for potential transplantation while cells were being evaluated for adequacy of quality and quantity. All potential recipients were fully evaluated and consented for an Investigational Review Board-approved protocol well before being contacted for possible transplantation. Communication between
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Ziv Neeman, MD, Boaz Hirshberg, MD, David Harlan, MD, and Bradford J. Wood, MD cell processing and the interventional radiology teams occurred at multiple stages during cell processing. Patients were brought to the interventional suite prior to the final islet counting and other assessments (eg, viability and endotoxin assays). Islet preparations deemed appropriate for transplant were infused via the portal vein. Patients were treated with daclizumab, sirolimus, and tacrolimus to prevent rejection.
Islet Cell Transplantation Technique (NIH Experience)
Standard intravenous conscious sedation (fentanyl and midazolam) was administered with routine hemodynamic, cardiac, and oxygen saturation monitoring. Glucose finger sticks were performed every 15 minutes throughout the entire procedure. The patient's abdomen was prepped and draped in sterile fashion. Prior to the transplantation, a comprehensive ultrasound of the patient's liver was performed in order to verify patency of the portal vein with normal hepatopetal flow, and normal Doppler signal. One percent lidocaine was administered locally subdermally with a 25G needle, followed by a 22G needle for anesthesia in a cylinder shape, down to the liver capsule. Under alternating ultrasound and fluoroscopic guidance, a peripheral portal vein tributary (usually on the right) was accessed ( Fig. 1) with a special portal vein access set consisting of a 15-or 20-cm 21G or 22G needle, a stiffened and elongated coaxial 3F/4F micropuncture set (Cook Group, Bloomington, IN), and an 0.018-inch nitinol guide wire using a modified Seldinger single wall puncture technique. Successful peripheral portal vein access was confirmed with contrast injection. After exchange to a 0.35-inch guide wire (usually a Rosen), a 4.1 F Kumpe catheter (Cook Group) with 0.025-inch side holes cut near the tip was inserted and guided into the main portal vein with the tip on the hepatic side of the confluence of portal, splenic, and mesenteric veins. A dedicated digital subtraction preprocedural portal venogram was obtained to assess for normal portal vein flow and to verify catheter placement in the main portal vein (Fig. 2) . Portal venous systolic and diastolic pressure monitoring was performed at baseline and at 5-minute intervals throughout the infusion. The islet preparation was divided into two to four 50-cm 3 syringes. All syringes were continuously inverted slowly and simultaneously rotated throughout the procedure to minimize clumping and to keep the islets in suspension. The total heparin dose was divided into one third in the islet medium, and two thirds direct bolus injection into the portal vein. Total dose of heparin was 50 U of heparin per kilogram of the recipient weight for the first two patients and 35 U/kg for the subsequent four patients. Islets were slowly infused via syringe over 60 to 90 minutes using a three-way stopcock. Because the islets were denser than the suspension medium, they tended to spontaneously pellet to the dependent portion of the syringe if left at rest. In order to promote hemostasis at the conclusion of the procedure, collagen Gelfoam (Pharmacia & Upjohn, Kalamazoo, MI) pledgets were injected under real-time ultrasound guidance just below the hepatic capsule into the parenchymal track, while drawing back the 4.1 F Kumpe catheter. Special attention and care were invested to ensure the pledgets lodged in the liver parenchyma and not in the portal vein. The catheter was removed during track embolization (with the placement of ~ 3-mm intraparenchymal Gelfoam pledgets) after waiting 60 minutes to let the heparin effect dissipate.
A postprocedure abdominal ultrasound survey was performed looking for free intraperitoneal, hepatorenal pouch, perihepatic or subcapsular fluid or blood. An ultrasound color Doppler analysis of the main, left, and right portal veins was performed to confirm continued patency. In the absence of symptoms, significant hemodynamic change, or other suspicious ultrasound findings, CT scans were not routinely obtained immediately following the procedures. A postprocedure ultrasound and Doppler evaluation were repeated within 24 hours after the procedure to assess for portal vein patency and bleeding. If there were clinical or radiographic suspicions, a CT was obtained as well. 
